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This article is based on a study first reported in Health Technology Assessment:
Harron K, Mok Q, Dwan K, Ridyard CH, Moitt T, Millar M, et al. CATheter
Infections in CHildren (CATCH): a randomised controlled trial and economic
evaluation comparing impregnated and standard central venous catheters in
children. Health Technol Assess 2016; 20(18), doi: 10.3310/hta20180
Background: Antibiotic-impregnated central venous catheters (CVCs) reduce the risk of
bloodstream infections (BSIs) in patients treated in pediatric intensive care units (PICUs).
However, it is unclear if they are cost-effective from the perspective of the National Health
Service (NHS) in the UK.
Methods: Economic evaluation alongside the CATCH trial (ISRCTN34884569) to
estimate the incremental cost effectiveness ratio (ICER) of antibiotic-impregnated
(rifampicin and minocycline), heparin-bonded and standard polyurethane CVCs. The
6-month costs of CVCs and hospital admissions and visits were determined from
administrative hospital data and case report forms.
Results: BSIs were detected in 3.59% (18/502) of patients randomized to standard,
1.44% (7/486) to antibiotic and 3.42% (17/497) to heparin CVCs. Lengths of hospital stay
did not differ between intervention groups. Total mean costs (95% confidence interval)
were: £45,663 (£41,647–£50,009) for antibiotic, £42,065 (£38,322–£46,110) for heparin,
and £44,503 (£40,619–£48,666) for standard CVCs. As heparin CVCs were not clinically
effective at reducing BSI rate compared to standard CVCs, they were considered not to
be cost-effective. The ICER for antibiotic vs. standard CVCs, of £54,057 per BSI avoided,
was sensitive to the analytical time horizon.
Conclusions: Substituting standard CVCs for antibiotic CVCs in PICUs will result in
reduced occurrence of BSI but there is uncertainty as to whether this would be a
cost-effective strategy for the NHS.
Keywords: cost-effectiveness analysis, bloodstream infection, central venous catheter, pediatric intensive care,
antibiotic, heparin
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INTRODUCTION
Central venous catheters (CVCs) are a large yet potentially
avoidable cause of health-care associated infections in hospitals.
In pediatric intensive care units (PICUs), catheter-related
bloodstream infections (BSIs) occur in 3–8% of all CVC
insertions (Hockenhull et al., 2008). BSIs are associated with
increased morbidity, mortality, lengths of hospital stay, and
healthcare costs (Abou Elella et al., 2010; Nowak et al., 2010).
Since between 40 and 60% (Harron et al., 2014) of the 16,000
annual admissions to English PICUs (PICANet, 2014) require
CVCs, BSIs represent amajor burden to patients and the National
Health Service (NHS) (Elward et al., 2005; Abou Elella et al.,
2010).
The incidence of BSI in adults may be reduced with CVCs
impregnated with antibiotics, antibacterial agents or heparin.
These are recommended for use in adults at highest risk of
BSI (Department of Health, 2007), but evidence in children is
lacking (Balain et al., 2015). CVC use in children presents a
greater theoretical risk of BSI owing to the narrower lumens
within which blood may thrombose more readily. The CATheter
Infections in Children (CATCH) trial (NCT01029717) was a
pragmatic, three-arm randomized controlled trial aimed to
determine the clinical and cost-effectiveness of antibiotic or
heparin CVCs compared with standard CVCs in children
requiring intensive care. Both heparin-bonded and antibiotic-
impregnated CVCs prevent biofilm formation which prevents
bacterial colonization. Heparin inhibits thrombus formation
and heparin-bonded CVCs use benzalkonium chloride as an
anti-infective bonding agent. The primary analyses of CATCH,
however, showed no effect of impregnated compared with
standard CVCs (Gilbert et al., 2016; Harron et al., 2016a); but
secondary analyses revealed antibiotic CVCs to be superior to
heparin CVCs with a hazard ratio (HR) for time to first BSI of
0.42 (95% CI, 0.19–0.93), and to standard polyurethane CVCs
(HR 0.43; 95% CI 0.20–0.96). Heparin CVCs were no different
from standard (HR 1.04; 95% CI, 0.53–2.03).
As impregnated CVCs are more expensive than standard,
decisions on their broader use within the NHS requires evidence
of their cost-effectiveness. Existing economic analyses are limited
in their applicability to the PICU setting in the UK as they relate
to adult populations and, with one exception (Hockenhull et al.,
2008), apply to different healthcare systems [Australia (Halton
et al., 2009), Germany (Frank et al., 2003), and the USA (Veenstra
et al., 1999; Marciante et al., 2003; Shorr et al., 2003)]. These
studies indicate, however, that antibiotic-impregnated CVCs are
associated with improved health outcomes and are cost saving.
Previous economic evaluations are reliant on modeled costs
and consequences of BSI using data from a range sources,
often observational studies. As such, they rely on assumed
attribution of hospital lengths of stay (the main cost driver) and
mortality to BSI. The economic evaluation which adopted an
NHS cost perspective assumed catheter-related BSIs increase the
length of hospital stay by 6 additional days in intensive care
units (ICU) and 5 additional days in a general medical ward
(Hockenhull et al., 2008). A US cohort study of 1,339 pediatric
cases of catheter-related BSI matched to controls by propensity-
score, identified a higher mean attributable length of stay of
19 days (Goudie et al., 2014). While this is comparable with
the 21 days excess length of stay estimated for BSI in pediatric
hematology/oncology patients (Wilson et al., 2014), studies of
this nature are based on retrospective observational data and are
prone to bias. Patients who are more ill are more likely to develop
BSI, making it difficult to separate the contribution of BSI to
excess length of stay from the underlying condition.
The aim of the present study was to assess the cost-
effectiveness of antibiotic and heparin CVCs relative to
commonly used standard polyurethane CVCs in a UK PICU
setting using data collected as part of the CATCH randomized
controlled trial.
METHODS
Design and Results of CATCH
CATCH recruited 1,485 children <16 years who were admitted
to any of 14 PICUs in England and who were expected to
require a CVC for≥3 days. Children were randomized equally to
receive heparin-bonded, antibiotic-impregnated (rifampicin and
minocycline), or standard polyurethane CVCs. The intervention
was blinded to everyone except the clinicians responsible for
inserting the catheter. The primary outcome was the time to
first BSI occurring between 48 h after randomization and 48 h
after CVC removal. This occurred in 3.59% (18/502) children
randomized to standard CVC, 1.44% (7/486) to antibiotic, and
3.42% (17/497) to heparin CVCs. In the primary analysis,
impregnated CVCs (antibiotic and heparin) were no more
effective than standard CVCs (HR 0.71; 95% CI 0.37–1.34).
Antibiotic CVCs were superior to standard CVCs in secondary
analysis (HR 0.43; 0.20–0.96) but heparin CVCs were not (HR
1.04; 0.53–2.03). There were no differences between intervention
groups in other outcomes, including time to thrombosis, 30-day
mortality, or antibiotic resistance (minocycline or rifampicin).
Trial results are presented in full elsewhere (Gilbert et al., 2016;
Harron et al., 2016a).
The CATCH trial is registered with the ClinicalTrials.gov
(Trial registration: NCT01029717 Registered 9 December 2009),
and was conducted in accordance with the recommendations of
the Research Ethics Committee for South West England, with
prospective or deferred written informed consent obtained from
all subjects in accordance with the Declaration of Helsinki. The
protocol was approved by the Research Ethics Committee for
South West England (reference number 09/H0206/69), and is
available at www.nets.nihr.ac.uk/projects/hta/081347.
Economic Evaluation
We conducted a cost-effectiveness analysis as it is not possible
to estimate health utilities in children in a PICU setting
(Thorrington and Eames, 2015). While this precluded any
evidence on allocative efficiency, it allowed for an assessment of
technical efficiency for selecting the most cost-effective CVC for
reducing the occurrence of BSIs.
Resource Use
The economic analysis adopted the perspective of the NHS
in England, with resource use measurement focused on the
principal cost drivers, which were PICU, High Dependency
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Unit (HDU) and ward stays (including readmissions), outpatient
clinic visits, Accident and Emergency (A&E) admissions and the
costs of the CVCs. The 6-month time horizon of the base-case
analysis was chosen to include the costs associated withmanaging
BSIs and associated complications. Shorter time horizons were
explored in sensitivity analyses.
Patients’ use of hospital services were obtained from trial
case report forms (CRF), Hospital Episode Statistics (HES),
the Paediatric Intensive Care Audit Network (PICANet), and
hospital Patient Administration Systems (PAS). CRFs were
accessed for data on dates of hospital discharge, transfer to other
hospitals and CVC removal. HES data on Healthcare Resource
Groups (HRGs) corresponding to the type of care patients receive
at a ward-level, outpatient visits and A&E admissions, were
accessed from NHS Digital1. We accessed the PICANet dataset2
for the National Schedule of Reference Cost HRGs for HDU and
ICU stays3, and for verifying the dates of hospital admission,
transfer and discharge. The finance offices of each participating
hospital provided data from Patient Administration Systems
(PAS) on patients’ lengths of stay in ICUs and wards, and on
relevant HRGs. These were used to supplement data that were
otherwise missing from other sources.
Costs Analysis
HRGs reflect NHS hospital payments for patients’ use of hospital
services. Unit costs from the 2012 to 2013 National Schedule
of Reference Costs were applied to all HRG codes; the most
significant being those associated with PICU, Neonatal Intensive
Care Unit (NICU) and HDU (Table 1). Basic HDU (XB07Z) or
ICU (XB05Z) codes were applied in the 10% of cases where HRG
codes were missing.
Unit costs of ward, outpatient and A&E attendances are
presented in the Supplementary Appendix Tables 1–3. Any
missing HRGs from HES or PAS data were replaced with ward
costs based on bed-day rates provided by hospital finance offices
(Supplementary Appendix Table 4). Bed-day rates were also
applied to unassignable HRG codes appearing in the HES and
PAS data, but overall, bed-day rates were used to cost <1% of
admissions.
Catheter list prices were provided by the supplier (Cook
Medical, Bloomington, IN, USA).
The costs of care for the 6-months prior to randomization
were calculated from HES and PICANet data. Given that HRGs
relate to episodes of care, we calculated patient costs for the
6-months following randomization according to:
Cost = (N/n+N) × (wardcost + PICUcost + HDUcost)
+ (outpatient costs + A&E costs + CVC costs)
Where n and N are the number of days patients were hospitalized
prior to, and following randomization, respectively.
1Health and Social Care Information Centre Data Linkage and Extract Service.
Available online at: http://www.hscic.gov.uk/dles (Accessed August 10, 2017).
2Paediatric Intensive Care Audit Network. Available online at:
http://www.picanet.org.uk/ (Accessed August 10, 2017).
3National Schedule of Reference Costs 2012-13. Available online at:
https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013
(Accessed August 10, 2017).
Patients’ use of healthcare resources and total costs were
calculated for the intention to treat population, and summary
statistics were generated by intervention group.
Outcomes
The health outcome for the cost-effectiveness analysis was the
presence of a first BSI. These were defined in CATCH by a
positive blood culture from a sample that was clinically indicated
and takenmore than 48 h after CVC insertion and up to 48 h after
CVC removal (Gilbert et al., 2016).
Incremental Analysis
Each CVC was ranked in order of decreasing effectiveness
and dominated interventions (those which are less effective or
ineffective) or extendedly dominated interventions eliminated.
The incremental cost effectiveness ratio (ICER) was calculated
for remaining CVCs as the difference in the means of total
costs divided by the difference in the proportion of bloodstream
infections.
Uncertainty Analysis
Bias-adjusted 95% central ranges for differences in costs and
BSI were calculated from 10,000 replicate bootstrap analyses.
The joint uncertainty in costs and BSI was depicted in a cost-
effectiveness acceptability curve (CEAC) which presented the
probability of CVCs being cost effective for different threshold
willingness to pay for each BSI averted (Fenwick et al., 2001).
Uncertainty in total costs was further assessed by adjusting
for the contribution of baseline factors to overall variability
(Mihaylova et al., 2011).
Sensitivity Analysis
Given the dependency of costs and therefore the ICER on the
analytic time horizon, a sensitivity analysis was performed in
which costs were limited to those incurred during the index
hospitalization (that is, excluding any re-admissions that may
have occurred over the 6-month period).
Regression Analysis
Regression analyses were performed to control for possible
baseline imbalances between intervention groups (Mihaylova
et al., 2011) and, by including a variable to representing the
presence of a BSI, to estimate the value of healthcare resources
associated with the management of BSI. The following pre-
specified variables were tested for their independent associations
with total costs: Age, body weight, 6-month pre-randomization
costs (all log-transformed), gender, pre-existing CVC 72 h prior
to randomization, health status before PICU admission, reason
for admission (cardiovascular, endocrine or metabolic, infection,
neurological, oncology, respiratory, trauma, other), suspected
infection at randomization, immune compromised, positive
blood culture within 72 h prior to randomization, numbers
of devices in situ, and admission type (elective or emergency).
Where data were missing, we assumed: patients to be healthy (n
= 1), not immunocompromised (n = 19), and no positive blood
culture (n = 5). Missing data for weight (n = 2) were imputed
with the mean (11.95 kg).
Variables that were significant at the 5% level were included
using a stepwise approach in multivariable generalized linear
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TABLE 1 | Unit cost for intensive care and high dependency care, based on HRGs from the National Schedule of Reference Costs (2012–13).
HRG code HRG name Description Cost per day (£)
XB01Z Pediatric critical care, intensive
care, ECMO/ECLS
Highly specialized intensive care treatment ECMO, VAD, and other highly complex
procedures
4,391
XB02Z Pediatric critical care, intensive
care, advanced enhanced
Unstable multi-system failure with other
complications
2,409
XB03Z Pediatric critical care, intensive
care, advanced
Intensive nursing supervision at all times,
undergoing complex monitoring and/or therapeutic
procedures, including advanced respiratory support
Invasive ventilation with multi-system
failure
2,017
XB04Z Pediatric critical care, intensive
care, basic enhanced
Intensive ventilation with more than one
system failure
2,110
XB05Z Pediatric critical care, intensive
care, basic
Continuous nursing supervision Invasive ventilation with single system
failure or non-invasive ventilation with
more than one system failure
1,743
XB06Z Pediatric critical care, high
dependency, advanced
Require closer observation and monitoring than is
usually available on an ordinary children’s ward, with
higher than usual staffing levels
Non-invasive ventilation (e.g., CPAP and
BiPAP by mask with IV drugs)
1,335
XB07Z Pediatric critical care, high
dependency
Close monitoring, oxygen by mask, no
invasive ventilation)
886
XB08Z Pediatric critical care,
transportation
Since pediatric critical care facilities are centralized in a small number of hospitals providing
expert specialist care, specialist transport teams are required to deliver clinical management
during transfer of patients
2,799
XA01Z Neonatal critical care, intensive
care
Care provided for babies who are the most unwell
or unstable and have the greatest needs in relation
to staff skills and staff to patient ratios
Baby receives any form of mechanical
respiratory support via a tracheal tube
and/or parenteral nutrition
1,118
ECMO, extra-corporeal membrane oxygenization; ECLS, extracorporeal life support; VAD, Ventricular assist devices; CPAP, Continuous Positive Airway Pressure; BiPAP, Bi-Level Positive
Air Pressure; IV, intravenous.
models (GLMs) that were specified using a combination
of families (e.g., gamma and poisson) and links (e.g., log,
square root and identity). Modified Park’s test and Akaike
Information Criterion were used to assess GLM goodness
of fit but were inconclusive. The identity link function
performed best according to the Pearson Correlation,
Pregibon Link, and the Modified Hosmer and Lemeshow
tests. We therefore specified an ordinary least squares
regression based on the comparatively large sample size
which guaranteed near-normality of sample means (Glick et al.,
2007).
All analyses were performed using STATA Version 10, and the
economic analysis was reported according to the Consolidated
Health Economic Evaluation Reporting Standards (CHEERS)
statement (Husereau et al., 2013).
RESULTS
Resource Use and Costs
Cost data were available for all patients. Hospital ICU/HDU
length of stay and total costs were comparable between
intervention groups during the 6-months prior to
randomization.
In the 6-months following randomization, patients
randomized to antibiotic-impregnated CVCs were in PICU
for a mean of 10.8 days (95% CI, 9.3–12.4), compared with 9.9
days (95% CI, 8.6–11.4) for those randomized to heparin-bonded
CVC and 10.5 days (95% CI, 9.2–11.9) for standard CVCs
(Table 2). Mean durations of hospitalization were 34.8 days
(95% CI, 31.2–38.5) for antibiotic-impregnated CVC, 31.4 days
(95% CI, 28.2–34.7) for heparin-bonded CVC and 31.7 (95%
CI, 28.8–34.7) for the standard CVC group. Six HRGs (from a
total of 349) relating to congenital or other cardiac surgery and
lower respiratory tract disorders, accounted for 50% of ward
costs.
Mean 6-month costs were £44,503 (median £28,952; range
£1,786–£360,983; 95% CI, £40,619–£48,666) for standard
CVC, £45,663 (median £29,793; range £2,189–£442,365; 95%
CI, £41,647–£50,009) for antibiotic-impregnated CVC, £42,065
(median £27,621; range £2,638–£382,431; 95% CI, £38,322–
£46,110) for heparin-bonded CVC (Table 3). Costs were
not significantly different by CVC group over the 6-month
timeframe.
Variables tested for the cost regression were evenly balanced
between intervention groups (Balain et al., 2015). The residual
variability in total cost could be explained, in part, by the
following significant explanatory variables: age (in days), 6-
month pre-randomization costs (both log-transformed), health
status at randomization, reason for admission, immune status,
and admission type (elective or emergency). The adjusted
incremental costs associated with antibiotic CVCs, in relation
to standard CVCs, were £1,220 (95% CI, −£4,332 to £6,773),
and with heparin CVCs, −£2,399 (95% CI, to −£7,914 to
£3,120).
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TABLE 2 | Patients’ lengths of stay from randomization to 6-months (including readmissions), according to place and intensity of care and by intervention group.
Unit Antibiotic CVC Heparin CVC Standard CVC
Mean 95% CI Mean 95% CI Mean 95% CI
Days on ICU 10.79 9.28, 12.48 9.91 8.57, 11.44 10.50 9.17, 11.93
Pediatric critical care, intensive care, ECMO/ECLS 0.30 0.07, 0.72 0.38 0.09, 0.80 0.40 0.17, 0.72
(XB01Z)
Pediatric critical care, intensive care, advanced 0.16 0.09, 0.26 0.12 0.09, 0.15 0.16 0.10, 0.26
enhanced (XB02Z)
Pediatric critical care, intensive care, advanced (XB03Z) 0.76 0.51, 1.05 0.61 0.43, 0.83 0.65 0.46, 0.87
Pediatric critical care, intensive care, basic enhanced 2.30 1.92, 2.72 2.68 2.09, 3.44 2.75 2.14, 3.54
(XB04Z)
Pediatric critical care, intensive care, basic (XB05Z) 6.96 5.65, 8.45 5.63 4.75, 6.59 6.40 5.42, 7.47
Neonatal critical care, intensive care (XA01C) 0.29 0.10, 0.55 0.46 0.13. 1.03 0.11 0.04, 0.20
Days on HDU 1.99 1.48, 2.62 1.59 1.28, 1.99 1.73 1.44, 2.05
Pediatric critical care, high dependency, advanced 1.27 0.94, 1.70 1.08 0.80, 1.45 1.22 0.98, 1.49
(XB06Z)
Pediatric critical care, high dependency (XB07Z) 0.71 0.42, 1.16 0.51 0.40, 0.64 0.51 0.40, 0.64
Days on ward 22.01 19.26, 24.80 19.84 17.40, 22.40 19.48 17.12, 21.94
Total days in hospital 34.80 31.21, 38.48 31.35 28.18, 34.65 31.71 28.75, 34.81
Count of non-PICU/HDU inpatient HRGs
Complex congenital surgery (EA24Z) 100 103 109
Intermediate congenital surgery (EA25Z) 68 70 72
Major complex congenital surgery (EA23Z) 45 39 37
Cardiac conditions with complication and comorbidity 109 102 74
(PA23A)
Lower Respiratory Tract Disorders without acute 95 78 105
bronchiolitis with length of stay ≥1 day with complication
and comorbidity (PA14C)
Implantation of prosthetic heart or ventricular assist 2 2 4
device (EA43Z)
Other inpatient HRGs 1,103 1,055 964
CVC, central venous catheter; CI, confidence interval; ICU, Intensive care unit; ECMO, extra-corporeal membrane oxygenization; ECLS, extracorporeal life support; HDU, High
dependence unit; PICU, Pediatric intensive care unit; HRGs, Healthcare Resource Groups.
Outcomes
Seven patients from 486 randomized to antibiotic CVCs
experienced a BSI, compared with 17/497 in the heparin CVC
group and 18/502 in the standard CVC group. A statistically
significant absolute risk differences was found only for antibiotic
vs. standard CVCs (−2.15%; 95% CI, −4.09 to −0.20). Heparin
CVCs were not clinically effective with a risk difference of
−0.17% (95% CI,−2.45 to 2.12) vs. standard CVC.
Value of Healthcare Resources Associated
with BSI
Patients who had a BSI (n= 42) experienced 6.5 more days (95%
CI, 1.4–11.6) in PICU than those with no BSI (n = 1,443), and
15.1 additional total days (95% CI, 4.0–26.2) of hospitalization.
Themean 6-month costs for patients with a BSI was £60,481 (95%
CI, £47,873–£73,809) compared to £43,578 (95% CI, £41,185–
£45,970) for those without; a difference of £17,263 (95% CI,
−£3,076 to £31,450). The adjusted difference in mean costs was
£10,975 (95% CI,−£2,801 to £24,751).
Incremental and Uncertainty Analysis
Heparin CVCs were not clinically effective when compared to
standard CVC, and are more expensive, and so cannot be cost-
effective by the same measure of BSI. The ICER for antibiotic-
impregnated vs. standard CVCs was £54,057 per BSI averted
(Table 4).
The probabilities of antibiotic CVCs being cost-effective at
thresholds of £10,000, £50,000, and £100,000 per BSI averted,
were 0.38, 0.49, and 0.62, respectively (Figure 1). There is a
probability of 0.650 for standard CVCs dominating antibiotic
CVCs.
Sensitivity Analysis
Considering only the index hospitalization, total costs in the
antibiotic CVC group were £33,073 (95% CI, £30,047–£36,337)
compared to £32,245 (95% CI, £29,013–£35,823) in the heparin
CVC group and £35,165 (95% CI, £31,864–£38,670) in the
standard CVC group. Antibiotic CVCs therefore dominated
standard CVC with a difference of 2.15% in the risk of BSI, and a
saving of £97,543 per BSI averted.
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TABLE 3 | Disaggregated and total costs (£) by intervention group from randomization to end of the 6-month timeframe.
Unit (code) Antibiotic CVC Heparin CVC Standard CVC
Mean 95% CI Mean 95% CI Mean 95% CI
Pediatric Critical Care, Intensive Care
ECMO/ECLS (XB01Z) 1,358 310, 3,159 1,703 386, 3,509 1,796 723, 3,156
Advanced enhanced (XB02Z) 388 207, 636 289 216, 371 395 228, 620
Advanced (XB03Z) 1,545 1,031, 2,124 1,250 872, 1,674 1,318 933, 1,752
Basic enhanced (XB04Z) 4,861 4,060, 5,738 5,675 4,418, 7,260 5,822 4,512, 7,460
Basic (XB05Z) 12,137 9,855, 14,730 9,822 8,274, 11,489 11,159 9,440, 13,025
Neonatal critical care, intensive care (XA01C) 325 113, 613 517 142, 1,150 125 42, 225
Pediatric Critical Care, HDU
High dependency, Advanced (XB06Z) 1,709 1,254, 2,271 1,450 1,972, 1,940 1,629 1,301, 1,992
High dependency (XB07Z) 635 372, 1,025 454 354, 567 456 356, 566
Transportation (XB08Z) 1,158 1,022, 1,293 1,258 1,109, 1,413 1,208 1,068, 1,353
Sub-total (PICU/HDU/NICU)a 24,115 20,824, 27,764 22,417 19,429, 25,771 23,907 20,989, 27,049
Inpatient Stayb
Complex congenital surgery (EA24Z) 3,011 2,445, 3,593 2,908 2,363, 3,481 3,144 2,565, 3,753
Intermediate congenital surgery (EA25Z) 2,166 1,670, 2,699 1,934 1,470, 2,440 2,044 1,583, 2,545
Major complex congenital surgery (EA23Z) 1,865 1,315, 2,481 1,915 1,310, 2,603 1,466 1,013, 1,960
Cardiac Conditions with complication and comorbidity 1,277 818, 1,845 1,173 831, 1,558 739 495, 1,025
(PA23A)
Lower respiratory tract disorders without acute 858 593, 1,157 668 454, 913 943 657, 1,268
bronchiolitis with length of stay ≥1 day with complication
and comorbidity (PA14C)
Implantation of prosthetic heart or ventricular assist 273 0, 684 298 0,762 548 103, 1,155
device (EA43Z)
Other inpatient HRG costs 10,316 8,616, 12,231 8,803 7,524, 10,106 9,930 7,860, 12,409
Sub-total (inpatient) 19,766 17,934, 21,755 17,700 16,308, 19,182 18,814 16,649, 21,327
A&E cost 89 76, 104 85 73, 99 91 78, 104
Outpatient cost 1,615 1,412, 1,838 1,784 1,496, 2,109 1,648 1,453, 1,871
CVC cost 78 78, 78 78 78, 78 43 43, 43
Total cost (full 6 months) 45,663 41,647, 50,009 42,065 38,322, 46,110 44,503 40,619, 48,666
aNational Schedule of Reference Costs 2012–2013;
bTop 6 (of 349) HRGs ranked by cost, together contributing 50% of overall inpatient cost, <1% taken from bed day rates.
CVC, central venous catheter; CI, confidence interval; ECMO, extra-corporeal membrane oxygenization; ECLS, extracorporeal life support; HDU, High dependence unit; PICU, Pediatric
intensive care unit; NICU, Neonatal intensive care unit; HRGs, Healthcare Resource Groups; A&E, Accident and Emergency.
DISCUSSION
The results of the base-case analysis indicate that heparin-
bonded CVCs are not cost-effective while the incremental cost-
effectiveness ratio of antibiotic-impregnated CVCs vs. standard
CVCs is £54,057 per BSI averted. However, there is considerable
uncertainty in this estimate. Restricting costs to the index hospital
stay resulted in an ICER of £97,543 saved per BSI averted
for antibiotic compared to standard CVCs. Antibiotic CVCs
are highly cost-effective when considering costs accruing over
comparable periods to events.
The economic analysis benefits from having been designed
and executed as an integral part of a pragmatic clinical trial that
provided an unbiased comparison of CVCs in the context of
current practice in 14 UK PICUs. The cost-effectiveness analysis
was conducted to accepted methodological standards of trial-
based economic evaluations (Ramsey et al., 2015). Patient-level
HES data were used to reflect NHS payments to hospitals for their
services, and we exploited different sources to ensure a complete
dataset.
However, there are limitations to the analysis. First, the
CATCH trial was not powered to demonstrate statistically
significant differences in effectiveness or costs among each of the
three types of CVCs. However, differences in the rates of BSI were
pre-specified in a secondary analysis, and a lack of a difference in
costs between intervention groups is less relevant in the context
of net benefits (Claxton, 1999). The joint uncertainty in costs
and BSI is considered in the CEAC which indicated antibiotic
CVCs as having a probability of 0.35 of dominating standard
CVCs. Despite not being effective at reducing BSI rates, the mean
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TABLE 4 | Incremental analysis.
Antibiotic CVC Heparin CVC Standard CVC
BASE-CASE ANALYSIS (6-MONTH TIME HORIZON)
Total costs £45,663
(£41,647,
£50,009)
£42,065
(£38,322,
£46,110)
£44,503
(£40,619,
£48,666)
Incremental cost
(vs. standard)
£1,160
(−£4,743, £6,692)
−£2,438
(−£8,164, £3,359)
–
BSI 1.44% (0.4, 2.5) 3.42%
(1.8, 5.0)
3.59%
(2.0, 5.2)
Incremental BSI (vs.
standard)
−2.15%
(−4.1, −0.2)
−0.17%
(−2.5, 2.1)
–
ICER (vs. standard) £54,057 per BSI
averted
–a –
SENSITIVITY ANALYSIS (INDEX HOSPITALIZATION)
Total costs £33,073
(£30,047,
£36,337)
£32,245
(£29,013,
£35,823)
£35,165
(£31,864,
£38,670)
Incremental cost
(vs. standard)
−£2,093
(−£6,919, £2,583)
−£2,920
(-£7,833, £2,180)
−
BSI 1.44% (0.4, 2.5) 3.42%
(1.8, 5.0)
3.59%
(2.0, 5.2)
Incremental BSI (vs.
standard)
−2.15%
(−4.1, −0.2)
−0.17%
(−2.5, 2.1)
−
ICER (vs. standard) −£97,543
per BSI avertedb
−
a
−
Values are means with 95% confidence intervals in parentheses.
aAs heparin CVC was not deemed to be clinically effective in reducing BSI rates, it cannot
be cost-effective by the same outcome measure.
BSI, bloodstream infection; ICER, incremental cost effectiveness ratio; CVC, central
venous catheter.
bCost saving.
FIGURE 1 | Cost-effectiveness acceptability curve presenting the probability
of antibiotic and standard CVCs being cost-effective for a given values of
ceiling ratio expressed as cost per bloodstream infection (BSI) averted.
costs associated with heparin CVCs were lower than for either
antibiotic or standard CVCs. This is likely to be explained by BSI
being a rare event, with associated costs diluted in the overall
costs of managing patients in intensive care.
A second limitation was in our choice of economic outcome.
The quality-adjusted life-year (QALY), which is the preferred
measure of health outcome for cost-utility analyses (National
Institute for Health and Care Excellence, 2013), could not be
estimated in the study population (Thorrington and Eames,
2015). The majority of trial participants (58%) were aged <1
year, and even if utilities were measured by proxy, these would
be unreliable, especially in the context of intensive care. Using
BSI averted as the denominator of the ICER calculation also fails
to fully capture other possible consequences of BSI, including
long term neurological defects, mortality, antibiotic resistance
(Falagas et al., 2007) and other adverse events (Tsai et al., 2016).
While neurological outcomes were not monitored in CATCH,
there were no differences in 30-day mortality for antibiotic
vs. standard (HR 0.96; 95% CI, 0.61–1.51) or for heparin vs.
standard CVC (HR 0.65; 95% CI, 0.40–1.07). There were also no
differences between intervention groups in microbial resistance
to minocycline or rifampicin, or in adverse event rates (Gilbert
et al., 2016; Harron et al., 2016a).
In contrast to QALYs, where an explicit threshold range
has been defined (£20,000–£30,000 per QALY gained for most
health technologies in the UK), there is no threshold for BSIs
averted. Interpretation may therefore be dependent on previous
economic evaluations, such as Shorr et al. (2003) who considered
US$9600 to be cost-effective, or assumptions concerning the
impact of BSI on health. For instance, if BSIs are assumed
to impair patients’ quality of life by a year, (i.e., 1 QALY
decrement on average), then antibiotic CVCs may not be cost-
effective.
The choice of analytical time horizon represents a further
limitation. Six months was selected to capture the costs
of subsequent hospital readmissions and transfers to other
hospitals. However, as the cost-effectiveness calculation
considered only the first BSI, costs accrued over time with no
corresponding change to the number of BSI (these all occurred
within 30 days). Consequently, the ICER continued to increase
over time.
Our estimates of the costs associated with the management
of BSI are broadly in line with other economic evaluations
(Hockenhull et al., 2008); however there are appreciable
differences in our estimate of the ICER. Previous economic
analyses indicated the dominance of antibiotic CVCs over
standard CVCs. Possible explanations for this discrepancy are
that model-based analyses are based on a synthesis of data
from disparate sources, require strong assumptions on the
attribution of hospital lengths of stay and mortality to BSI and
assume independence of the cost of managing BSIs and CVC
type.
In conclusion, the results of the economic evaluation
indicate that replacing standard polyurethane CVCs with
antibiotic-impregnated CVCs in PICUs will result in reduced
rates of BSI. Given the low background rate of BSI, the
variation in costs between CVCs and the sensitivity of the
ICER to the time-horizon of analysis, it remains uncertain
if antibiotic-impregnated CVCs are cost-effective from a UK
NHS perspective. Given the focus of the evaluation, there
is limited generalizability outside the UK to other payers,
healthcare systems or jurisdictions; however, our economic
findings from CATCH add to evidence on the generalizability of
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trial participants in the UK, and on the cost implications of using
antibiotic-impregnated CVCs to the NHS (Harron et al., 2016b).
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